Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials.

ABSTRACT:

Importance

Randomized clinical trials have shown that implantable cardioverter-defibrillator (ICD) therapy saves lives. Whether the survival of patients who received an ICD in primary prevention clinical trials differs from that of trial-eligible patients receiving a primary prevention ICD in clinical practice is unknown.

Objective

To determine whether trial-eligible patients who received a primary prevention ICD as documented in a large national registry have a survival rate that differs from the survival rate of similar patients who received an ICD in the 2 largest primary prevention clinical trials, MADIT-II (n = 742) and SCD-HeFT (n = 829).

Design, setting, and patients

Retrospective analysis of data for patients enrolled in the National Cardiovascular Data Regist

SUBMITTER: Al-Khatib SM 

PROVIDER: S-EPMC3638257 | biostudies-literature | 2013 Jan

REPOSITORIES: biostudies-literature